2 variants of Zika vaccine ready
NEW DELHI: Within days of the US government and French pharma major Sanofi announcing they had launched an effort to develop a Zika vaccine, Hyderabadbased Bharat Biotech said on Wednesday it had two variants ready for pre- clinical studies, one recombinant and the other inactivated.
A recombinant vaccine involves DNA encoding that stimulates an immune response while an inactivated one consists of virus particles grown under controlled conditions and rendered non-infectious.
“We have two candidate vaccines in development. One of them is an inactivated vaccine that has reached the stage of pre- clinical testing in animals,” company chairman and managing director Dr Krishna Ella said, adding that pre- clinical trials would take five months.
The Indian Council of Medical Research (ICMR) will examine the claim made by the firm this week.
“It is worth looking at. The committee will first need to validate the claim, but looking at the global situation, we will work as quickly as possible,” said Dr Soumya Swaminathan, directorgeneral of the umbrella research organisation.
CONTINUED ON P12